Ipamorelin Overview

Ipamorelin is a synthetic pentapeptide and selective agonist of the ghrelin receptor (GHS-R1a). It is studied in preclinical and clinical research for its ability to stimulate growth hormone release without significantly affecting cortisol or prolactin. Its selective activity makes it an important tool for investigating endocrine signaling, growth hormone regulation, and related cellular pathways.

Svensson J. et al. (1998).

History

Ipamorelin was developed in the 1990s during research into growth hormone secretagogues (GHS). Unlike earlier compounds such as GHRP-6, Ipamorelin demonstrated greater selectivity, stimulating GH release with minimal off-target hormonal effects. Since its discovery, it has been applied in studies investigating pituitary regulation, GH-dependent signaling, and metabolic pathways in laboratory models.

Bowers C.Y. et al. (1997).

Ipamorelin Structure

CAS #: 170851-70-4

Molecular Formula: C₃₈H₄₉N₉O₅

Molecular Weight: 711.9 g/mol

PubChem ID: 9831659

Research Findings

Ipamorelin has been studied in endocrine, metabolic, and regenerative models, with research highlighting its activity in stimulating growth hormone release, modulating IGF-1 pathways, and supporting tissue recovery processes. Studies have also examined its role in metabolic regulation, energy balance, and cellular repair in preclinical systems.

Key Areas of Research:

• Endocrine: GH release, IGF-1 signaling, pathways

• Metabolic: energy balance, glucose regulation

• Cellular: repair, proliferation, recovery

Together, these findings suggest experimental utility for Ipamorelin across multiple biological pathways. By influencing growth hormone secretion and downstream metabolic and regenerative processes, Ipamorelin provides a versatile platform for research into tissue recovery, endocrine activity, and systemic resilience in laboratory models.

Raun K. et al., 1998

References

Svensson J. et al. (1998). Ipamorelin selectively stimulates GH release in humans without affecting cortisol or prolactin. J Clin Endocrinol Metab, 83(9):3094–3101. 

Bowers C.Y. et al. (1997). Ipamorelin: a novel pentapeptide GH secretagogue. Endocrinology, 138(9): 4011–4016. 

Culler M.D. et al. (2002). Pharmacological characterization of Ipamorelin, a GHRP with GH selectivity. J Endocrinol, 174(2):R1–R6.